ArticleAnnals of medicine2025
Long-term healthcare use of COVID-19 cases in 2020: a two-year follow-up in Stockholm, Sweden.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited data on whether SARS-CoV-2 infections will result in increased long-term use of general healthcare, potentially impacting healthcare systems and management. Exploring this, we investigated the healthcare use of individuals with a SARS-CoV-2 infection in 2020 over a period of two years, using comprehensive medical records.
methodsWe followed a cohort of 365,354 individuals in Stockholm, Sweden, who had been tested with SARS-CoV-2 serology in 2020, for healthcare use during 2021/22. SARS-CoV-2 seropositive and seronegative individuals were matched 1:1 on age, sex, 2019 healthcare use, and date of last serology, and compared on healthcare use during 2021/22 using registry linkages. Seropositive individuals were stratified on hospitalization for COVID-19 in 2020. Individuals were compared for total healthcare use, measured as incidence rate rations (IRR), and healthcare type usage-or-not per month, measured as a difference-in-differences regression.
resultsThere were 272,918 seronegative and 73,814 seropositive subjects. Incidence rate ratios (IRRs) for primary healthcare use were 1.0, 1.16, and 0.98, for all, only hospitalized, and only non-hospitalized, seropositive individuals respectively. For outpatient specialist care IRRs were 0.96, 1.31, and 0.93. For inpatient care IRRs were 0.98, 1.19, and 0.95. Healthcare type usage-or-not per month showed no substantial differences, ranging from 0.01 to -0.01 in deviation. Increased healthcare use during follow-up was restricted to the seropositive individuals hospitalized for COVID-19 in 2020.
conclusionThere was no increase in healthcare use in the overall population from SARS-CoV-2 infections during 2020, suggesting there is no apparent need to adapt healthcare systems at scale for the COVID-19 aftermath.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.